title: [New clinical staging system for carcinoma of nasal cavity].
abstract: OBJECTIVE
  To establish a new staging system based on analysis of several presently used clinical staging systems for carcinoma of nasal cavity.
  
  
  METHODS
  The data of 122 patients treated from 1985 to 1997 in the cancer center of Sun Yat-sen University were analyzed, and a new clinical staging system was established using computer optimizing and screening combined with the clinical results. The survival analysis was performed by Kaplan-Meier estimates, and the multivariate analysis was achieved by Cox proportional hazard model.
  
  
  RESULTS
  The flaws in the presently used clinical staging systems proposed by Zhuang, Qiu, Department of Head and Neck of Cancer Center of Sun Yat-sen University and University of Florida and the AJCC'2002, were as follows: insufficient consideration of the modern tomography resulting in indefinite location of the tumor in clinical practice, the uneven distribution of patients in different stages, being unable to separate survival curves of different stages, and not containing of all necessary clinical staging information in some staging systems. However, based on our new staging system, the cases distributed in T1, T2, T3 and T4 was 16, 32, 42 and 32, and the 5-year survival rate was 78.8%, 64.6%, 49.9% and 30.0%, respectively. The cases distributed in stage I, II, III and IV was 16, 26, 45 and 35, and the 5-year survival rate was 78.8%, 68.4%, 51.3% and 29.0%, respectively. The overall 5-year survival rate was 61.6%.
  
  
  CONCLUSIONS
  Compared to the presently used clinical staging systems, the new staging system may have more advantages in various parameters for the clinical staging in the carcinoma of nasal cavity, and may be worth to be widely and clinical used.
authors.affiliation: Department of Radiation Oncology, Cancer Center, Sun Yat-sen University, Guangzhou 510060, China. huweihan@163.com
authors.forename: Wei-han
authors.initials: WH
authors.lastname: Hu
authors.forename: Yan-li
authors.initials: YL
authors.lastname: Zhao
authors.forename: Sheng-hua
authors.initials: SH
authors.lastname: Fang
authors.forename: Fei
authors.initials: F
authors.lastname: Han
authors.forename: Guo-ting
authors.initials: GT
authors.lastname: Kuang
authors.forename: Hui
authors.initials: H
authors.lastname: Liu
authors.forename: Li-xia
authors.initials: LX
authors.lastname: Lu
authors.forename: Jie
authors.initials: J
authors.lastname: Yan
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009296:Nasal Cavity; D009367:Neoplasm Staging / Q000592:standards*; D009669:Nose Neoplasms / Q000401:mortality / Q000473:pathology*; D016016:Proportional Hazards Models; D012015:Reference Standards; D016019:Survival Analysis